Cambridge biotech STORM Therapeutics raises $56M
STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human trials. Phase 1 showed durable tumour regression across multiple sarcoma subtypes. The $56M Series C is backed entirely by existing investors including Pfizer Ventures and M Ventures. STORM Therapeutics, a Cambridge-based clinical-stage biotech targeting RNA modifications to treat cancer, has raised $56 million in […]<br /> This story continues at The Next Web [...]
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
Cambridge Audio unveils three wireless bookshelf speakers at CES
Cambridge Audio has three new active speakers at CES 2026. The L/R Series is a trio of active bookshelf-style speakers, each with wired and wireless modes.The flagship L/R X is an 800W model (400W per [...]
The new Storm Radar app is a treasure trove of data for weather nerds
The horrible winter of 2026 is behind us in New England; now we’ve moved on to the season where there’s a threat of rain basically every day. Given that, the updated Storm Radar app from The Weath [...]
Viking Therapeutics closer to bringing its Ozempic competitor to market
Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year partnership with CordenPharma, a leading contract manufacturing firm.Read more... [...]
The Last of Us season two 'The Path' recap: The calm after the storm before the storm
There’s an understandable and undeniable pall hanging over The Last of Us after last week’s shocker. And it’s the calm before the storm that’ll make up the rest of the season: Ellie and Dina†[...]
Danish biotech Cellugy wants to replace microplastics in cosmetics
Danish biotech Cellugy has raised €8.1mn in EU funding to accelerate production of a biodegradable material designed to replace microplastics in cosmetics. The grant, awarded under the EU’s LIFE P [...]
